RESUMO
OBJECTIVE: To evaluate the association of early continuous infusions of opioids and/or midazolam with survival and sensorimotor outcomes at age 2 years in very premature infants who were ventilated. STUDY DESIGN: This national observational study included premature infants born before 32 weeks of gestation intubated within 1 hour after birth and still intubated at 24 hours from the French EPIPAGE 2 cohort. Infants only treated with bolus were excluded. Treated infants received continuous opioid and/or midazolam infusion started before 7 days of life and before the first extubation. Naive infants did not receive these treatments before the first extubation, or received them after the first week of life, or never received them. This study compared treated (n = 450) vs naive (n = 472) infants by using inverse probability of treatment weighting after multiple imputation in chained equations. The primary outcomes were survival and survival without moderate or severe neuromotor or sensory impairment at age 2 years. RESULTS: Survival at age 2 years was significantly higher in the treated group (92.5% vs 87.9%, risk difference, 4.7%; 95% CI, 0.3-9.1; P = .037), but treated and naive infants did not significantly differ for survival without moderate or severe neuromotor or sensory impairment (86.6% vs 81.3%; risk difference, 5.3%; 95% CI -0.3 to 11.0; P = .063). These results were confirmed by sensitivity analyses using 5 alternative models. CONCLUSIONS: Continuous opioid and/or midazolam infusions in very premature infants during initial mechanical ventilation that continued past 24 hours of life were associated with improved survival without any difference in moderate or severe sensorimotor impairments at age 2 years.
Assuntos
Analgésicos Opioides/administração & dosagem , Recém-Nascido Prematuro , Midazolam/administração & dosagem , Transtornos do Neurodesenvolvimento/epidemiologia , Respiração Artificial , Estudos de Coortes , Feminino , França/epidemiologia , Humanos , Hipnóticos e Sedativos/administração & dosagem , Lactente , Recém-Nascido , Infusões Intravenosas , Estudos Longitudinais , Masculino , Taxa de SobrevidaRESUMO
This study followed 173 newborn infants in the PREmedication Trial for Tracheal Intubation of the NEOnate multicenter, double-blind, randomized controlled trial of atropine-propofol vs atropine-atracurium-sufentanil for premedication before nonemergency intubation. At 2 years of corrected age, there was no significant difference between the groups in death or risk of neurodevelopmental delay assessed with the Ages and Stages Questionnaire. Trial registration Clinicaltrials.gov: NCT01490580.
Assuntos
Adjuvantes Anestésicos/administração & dosagem , Anestésicos Combinados/administração & dosagem , Atracúrio/administração & dosagem , Atropina/administração & dosagem , Intubação Intratraqueal , Sistema Nervoso/crescimento & desenvolvimento , Propofol/administração & dosagem , Sufentanil/administração & dosagem , Pré-Escolar , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Recém-Nascido , Masculino , Fatores de Tempo , Resultado do TratamentoRESUMO
OBJECTIVE: To study the effects of dopamine on systemic arterial pressure (SAP) and systemic blood flow (SBF) (estimated with the superior vena cava [SVC] flow) in preterm infants with hypotension and patent ductus arteriosus (PDA). STUDY DESIGN: Clinical and echocardiographic variables were measured before and 2 hours after starting dopamine in premature infants <32 weeks gestational age with PDA and systemic hypotension. RESULTS: Seventeen premature infants were included (gestational age, 28+/-2 weeks; birth weight, 1030 +/- 400 g). A mean rate of 8 +/- 2 microg/kg/min of dopamine raised SAP from 30 +/- 3 to 41 +/- 5 mm Hg (P < .05), and the pulmonary artery pressures from 25 +/- 5 to 32 +/- 8 mm Hg (P < .05). The SVC flow increased by 30% (from 130 +/- 40 to 170 +/- 44 mL/kg/min; P < .05). The left ventricular output and the end-diastolic and mean left pulmonary artery blood flow velocities did not change despite the increase in pulmonary artery pressure. CONCLUSION: In preterm infants with hypotension and PDA, dopamine (<10 microg/kg/min) increases the systemic blood pressure and the systemic blood flow. Our results suggest that dopamine decreases left-to-right shunting across ductus arteriosus, caused by a rise in pulmonary vascular resistances.
Assuntos
Cardiotônicos/uso terapêutico , Dopamina/uso terapêutico , Permeabilidade do Canal Arterial/complicações , Hipotensão/tratamento farmacológico , Hipotensão/etiologia , Pressão Sanguínea/efeitos dos fármacos , Eletrocardiografia , França , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Unidades de Terapia Intensiva Neonatal , Estudos ProspectivosRESUMO
OBJECTIVE: To evaluate the respiratory and the pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension (PPHN)-induced cardiac dysfunction. STUDY DESIGN: Inclusion criteria were: 1) Newborn infants >35 weeks gestational age; 2) PPHN treated with inhaled nitric oxide; and 3) symptoms of circulatory failure despite adequate fluid resuscitation. Lung function and pulmonary hemodynamic variables assessed with Doppler echocardiography were recorded prospectively before and after starting norepinephrine. RESULTS: Eighteen newborns were included (gestational age: 37 +/- 3 weeks; birth weight: 2800 +/- 700 g). After starting norepinephrine, systemic pressure and left ventricular output increased respectively from 33 +/- 4 mm Hg to 49 +/- 4 mm Hg and from 172 +/- 79 mL/kg/min to 209+/-90 mL/kg/min (P < .05). Although the mechanical ventilatory variables have not been changed, the post-ductal transcutaneous arterial oxygen saturation increased from 89% +/- 1% to 95% +/- 4%, whereas the oxygen need decreased from 51% +/- 24% to 41% +/- 20% (P < .05). The pulmonary/systemic pressure ratio decreased from 0.98 +/- 0.1 to 0.87 +/- 0.1 (P < .05). Mean left pulmonary artery blood flow velocity increased by 20% (P < .05). CONCLUSION: Norepinephrine may improve lung function in newborn infants with PPHN through a decrease in pulmonary/systemic artery pressure ratio and improved cardiac performance.
Assuntos
Agonistas alfa-Adrenérgicos/uso terapêutico , Hipertensão Pulmonar/fisiopatologia , Norepinefrina/uso terapêutico , Circulação Pulmonar/efeitos dos fármacos , Agonistas alfa-Adrenérgicos/administração & dosagem , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Seguimentos , Humanos , Hipertensão Pulmonar/tratamento farmacológico , Recém-Nascido , Infusões Intravenosas , Norepinefrina/administração & dosagem , Oximetria , Estudos Prospectivos , Artéria Pulmonar/fisiopatologia , Circulação Pulmonar/fisiologia , Pressão Propulsora Pulmonar/efeitos dos fármacos , Resultado do TratamentoRESUMO
OBJECTIVE: To study the incidence of Kawasaki disease in the population of the French West Indies. METHODS: Fifty-six children where enrolled between January 1, 1995 and December 31, 2000), in this retrospective study in Guadeloupe (French West Indies), according to the diagnostic criteria of the American Heart Association. RESULTS: There were 31 boys and 25 girls. Their mean age at the time of diagnosis was 26.5 +/- 22 months. The mean incidence was 25.4/100 000 children aged under 5, per year. Cardiac involvement was noted in 17.8% of the cases during the first 3 months, with good outcome in all the children followed-up. CONCLUSION: The incidence of Kawasaki disease in Guadeloupe is high. The absence of epidemiological, clinical or biological predictive criteria of cardiac involvement should prompt the early use of immunoglobulins, notably in atypical presentations of the disease.